Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season

PR Newswire - Mon Jul 17, 2023

SUMMIT, N.J., July 17, 2023 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX:CSL), today announced it has begun to ship its portfolio of innovative cell-based, adjuvanted and egg-based influenza vaccines across the U.S. in preparation for the 2023/24 influenza season. The company is positioned to supply over 55 million doses of influenza vaccines to healthcare providers across the U.S.

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

Tensions rise in Silicon Valley over sales of startup stocks

inside the market

How pro money managers are balancing exposure to Canadian and U.S. stocks

At the open: North American stock markets rise as rate-cut hopes linger

The close: Wall Street sharply higher as nonfarm payrolls report strengthens case for rate cuts in both the U.S. and Canada

The close: Major North American indexes higher, led by Nasdaq, amid plethora of mixed earnings

international business

Trump awarded 36 million more Trump Media shares worth $1.8-billion after hitting price benchmarks

investor newsletter

The key to successful investing. Plus, why Fairfax Financial is poised for an extraordinary run

The close: Stocks mixed as Fed leaves investors guessing as to when rate cuts will arrive